Literature DB >> 26668693

Treating morbid obesity in cirrhosis: A quest of holy grail.

Naveen Kumar1, Narendra Singh Choudhary1.   

Abstract

The problem of obesity is increasing worldwide in epidemic proportions; the situation is similarly becoming more common in patients with cirrhosis which negatively affect the prognosis of disease and also makes liver transplantation difficult especially in the living donor liver transplantation setting where low graft to recipient weight ratio negatively affects survival. Treatment of obesity is difficult in cirrhosis due to difficulty in implementation of lifestyle measures, limited data on safety of anti-obesity drugs and high risk of surgery. Currently approved anti-obesity drugs have limited data in patients with cirrhosis. Bariatric surgery remains an option in selected compensated cirrhotic patients. Endoscopic interventions for obesity are emerging and are quite promising in patients with cirrhosis as these are minimally invasive. In present review, we briefly discuss various modalities of weight reduction in obese patients and their applicability in patients with cirrhosis.

Entities:  

Keywords:  Antiobesity drugs; Bariatric surgery; Cirrhosis; Intragastric balloon; Obesity

Year:  2015        PMID: 26668693      PMCID: PMC4670953          DOI: 10.4254/wjh.v7.i28.2819

Source DB:  PubMed          Journal:  World J Hepatol


  83 in total

Review 1.  From fat to inflammation.

Authors:  Christopher Paul Day
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

2.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

Review 3.  Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies.

Authors:  Yi Chen; Xiaolin Wang; Jianhua Wang; Zhiping Yan; Jianjun Luo
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

4.  Innovative approach using an intragastric balloon for weight loss in a morbidly obese patient undergoing liver transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Neeraj Saraf; Rajesh Puri; Arvinder Soin
Journal:  Liver Transpl       Date:  2012-12-12       Impact factor: 5.799

5.  Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus.

Authors:  Ichiro Konishi; Yoichi Hiasa; Yoshio Tokumoto; Masanori Abe; Shinya Furukawa; Kumiko Toshimitsu; Bunzo Matsuura; Morikazu Onji
Journal:  Hepatol Res       Date:  2011-06-28       Impact factor: 4.288

Review 6.  Extrahepatic complications of nonalcoholic fatty liver disease.

Authors:  Matthew J Armstrong; Leon A Adams; Ali Canbay; Wing-Kin Syn
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

7.  BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients.

Authors:  A Genco; T Bruni; S B Doldi; P Forestieri; M Marino; L Busetto; C Giardiello; L Angrisani; L Pecchioli; P Stornelli; F Puglisi; M Alkilani; A Nigri; N Di Lorenzo; F Furbetta; A Cascardo; M Cipriano; M Lorenzo; N Basso
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

8.  Cetilistat for the treatment of obesity.

Authors:  J Gras
Journal:  Drugs Today (Barc)       Date:  2013-12       Impact factor: 2.245

Review 9.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

Review 10.  The role of fatty acids in the development and progression of nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Michael J Pagliassotti
Journal:  J Nutr Biochem       Date:  2008-04-21       Impact factor: 6.048

View more
  3 in total

Review 1.  A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient.

Authors:  Edgewood R Warner; Fuad Z Aloor; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2022-01-25

Review 2.  Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Shuhei Nishiguchi; Hiroko Iijima
Journal:  Int J Mol Sci       Date:  2021-02-15       Impact factor: 5.923

Review 3.  Obesity in the Liver Transplant Setting.

Authors:  Carlos Moctezuma-Velazquez; Ernesto Márquez-Guillén; Aldo Torre
Journal:  Nutrients       Date:  2019-10-23       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.